


<p><b>INFORMAZIONI PERSONALI</b></p> 	<p><b>MARCHETTI MONIA</b></p> <p>Email: <a href="mailto:monia.marchetti@uniupo.it">monia.marchetti@uniupo.it</a></p> <p>PEC: <a href="mailto:monia.marchetti@pec.ordinemedicipavia.it">monia.marchetti@pec.ordinemedicipavia.it</a></p> <p>Telefono: +39 3470769270</p> <p>Sesso: femminile    Data di nascita: 31-07-1971</p> <p>Residenza: via don Minzoni 54, 27058 Voghera (PV)</p> <p>Ordine dei Medici di Pavia n. 6907</p> <p>Codice Fiscale: MRCMNO71L71G535U</p>
<p><b>ESPERIENZA PROFESSIONALE</b></p> <p>01/01/2020 – Esperienza attuale</p> <p>17/05/2006-31/12/2019</p> <p>01/08/2005-16/05/2006</p> <p>01/08/2002-31/07/2005</p> <p>01/11/2001-31/07/2002</p>	<p>Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo, Alessandria – DIRIGENTE MEDICO – Unità di EMATOLOGIA.</p> <p>Professore a contratto – UNIVERSITA’ del PIEMONTE ORIENTALE</p> <p>Ospedale Cardinal Massaia, ASL AT DIRIGENTE MEDICO – Unità di ONCOLOGIA – Responsabile del Day Hospital EMATOLOGICO</p> <p>IRCCS Policlinico San Matteo, Pavia CONTRATTISTA di RICERCA --Progetto di Ricerca UE “ An European Network for research in Myelofibrosis. Consensus on definition of disease improvement and biologic impact of new therapies” e del Progetto di ricerca UE “Strengthen and develop scientific and technological excellence in research and therapy of Leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration of the leading national leukemia networks and their interdisciplinary partner groups in Europe (European LeukemiaNet)”</p> <p>IRCCS Policlinico San Matteo, Pavia CONTRATTISTA di RICERCA – Ricerca Finalizzata del Ministero della Salute “Analisi genomica delle metastasi e dei vasi tumorali umani: potenziale target diagnostico e terapeutico” e nell’ambito della Ricerca Finalizzata del Ministero della Salute “Correlazione tra l’espressione di specifiche isoforme di un enzima chiave per la sintesi di citochine proinfiammatorie e malattie autoimmunitarie”</p> <p>IRCCS Policlinico San Matteo, Pavia BORSISTA di RICERCA – progetto AIRC: “An Italian network for clinical research in myelofibrosis with myeloid</p>

<p>01/11/1995-31/10/1996</p>	<p>metaplasia: low-dose oral etoposide versus standard dose hydroxyurea to control disease progression”</p> <p>IRCCS Policlinico San Matteo, Pavia BORSISTA di RICERCA – Ricerca Finalizzata Ministero della Salute “Progettazione e sviluppo di un sistema informatico basato sulla cooperazione tra agenti”</p>
<p><b>ISTRUZIONE e FORMAZIONE</b></p> <p>01/11/2004-31/10/2007</p> <p>01/11/1996-31/10/2001</p> <p>01/10/1989-20/07/1995</p>	<p>Università degli Studi di Pavia DOTTORATO di RICERCA in Medicina Interna</p> <p>Università degli Studi di Pavia Scuola di SPECIALIZZAZIONE in Medicina Interna Conseguimento Diploma di Specializzazione con votazione 50/50 cum laude</p> <p>Università degli Studi di Pavia Facoltà di Medicina e Chirurgia Conseguimento Diploma di Laurea con votazione 110/110 cum laude</p>
<p><b>DOCENZA</b></p> <p>09/07/2020-</p> <p>aa 2020/2021</p> <p>marzo 2021</p>	<p>Ministero dell’Università e della Ricerca Abilitazione Scientifica Nazionale a Professore di II fascia disciplina 06/D3 Ematologia (bando D.D. 2175/2018)</p> <p>Docente a contratto Università Piemonte Orientale: CdL Igiene Dentale – Corso di Medicina Interna Scuola di Specializzazione di Ematologia</p> <p>Docente Curvatura Biomedica – Liceo Vercelli – Asti</p>
<p><b>COMPETENZE PERSONALI</b></p> <p>Lingua Madre</p> <p>Lingua Inglese</p>	<p>Italiano</p> <p>Comprensione (ascolto): ottima Comprensione (lettura): ottima Parlato (interazione): ottima Parlato (produzione orale): ottima Produzione scritta (testi scientifici): ottima</p>
<p>Competenze organizzative</p>	<p>Coordinatore del registro Italiano della Mielofibrosi dal 2001 al 2006</p>

	<p>Coordinatore dell'attività clinica ematologica dell'Ospedale C Massaia di Asti dal 2013 al 2019</p> <p>Coordinazione di progetti di elaborazione linee-guida nazionali e internazionali (SIE, LeukemiaNet, EBMT, SIDEM/GITMO, SITE, EUMNET)</p>
Competenze informatiche	Office, Excel avanzato, Access, FileMakerPro, Tree-Age, STATISTICA
Sport	Atletica (fondo e mezzo-fondo agonistici), Nuoto
Patente di Guida	Patente B
<b>INDICI BIBLIOMETRICI</b>	<a href="https://orcid.org/0000-0001-7615-0572">https://orcid.org/0000-0001-7615-0572</a>
Pubblicazioni	114 pubblicazioni internazionali peer-reviewed 1 educativa ASH 5 pubblicazioni originali in lingua italiana 1 capitolo di libro in lingua italiana
Citazioni	4047 (Scopus 16-09-2021)
h-index	34 (Scopus 16-09-2021)
Top Italian Scientists	Ranked 1644 in Biomedical Sciences
Google Scholar	6316 citations h-index 41 <a href="https://scholar.google.com/citations?view_op=list_works&amp;hl=it&amp;user=DFG2v1cAAAAJ">https://scholar.google.com/citations?view_op=list_works&amp;hl=it&amp;user=DFG2v1cAAAAJ</a>
<b>ATTIVITA' EDITORIALE</b>	<p>Guest Editor dello special issue "Immunotherapy against Myeloma" per Vaccine (2021)</p> <p>Guest Editor dello special issue "Advanced therapies for Chronic Lymphocytic leukemia and related diseases" per il Journal of Clinical Medicine (2021)</p>
<b>RESPONSABILITA' di PROGETTI</b>	<p>IMPLEMENTAZIONE e COORDINAZIONE del Registro Italiano della Mielofibrosi dal 1999 al 2007: RETE NAZIONALE di RICERCA di oltre 300 centri clinici e anatomo-patologici.</p> <p>EUMNET (European Myelofibrosis Network) - COORDINATORE metodologico dello sviluppo dei CRITERI DI RIPOSTA al TRATTAMENTO dei pazienti con MIELOFIBROSI-2004-2005</p>

RESPONSABILE DEL TRIAL DI FASE II multicentrico CON TALIDOMIDE a basse dosi NEI PAZIENTI CON MIELOFIBROSI dal 01-06-2002 al 01-09-2004

IDEATORE E RESPONSABILE DELLO STUDIO "P-for-P: supporto tra pari nella gestione della Leucemia Linfatica Cronica e del Linfoma Follicolare"

European LEUKEMIANET – COORDINATORE dello sviluppo di LINEE-GUIDA per l'impiego di RUXOLINIB nei pazienti con MIELOFIBROSI – 2015-2016

European LEUKEMIANET – Revisione delle LINEE-GUIDA per gestione delle Malattie Mieloproliferative Croniche Ph- – 2017-2018

COORDINATORE dello SVILUPPO di LINEE-GUIDA basate sull'EVIDENZA (GRADE/ADAPTE) all'interno del COMITATO METODOLOGICO LINEE-GUIDA della SOCIETA' ITALIANA DI EMATOLOGIA dal 2001 ad oggi. Coautore di 14 linee-guida. Attualmente responsabile dello sviluppo di "Clinical Practice Recommendations" per il Mieloma Multiplo e il Tromboembolismo Venoso all'interno del SLNG (Sistema Nazionale Linee-Guida) /ISS.

Coordinatore dell'implementazione informatica delle raccomandazioni stesse con il supporto di score dinamici: <http://www.siematologia.it/raccomandazioni-linee-guida>

EBMT (European Society for Blood and Marrow Transplantation) – Responsabile Metodologico delle RACCOMANDAZIONI 2019 per la gestione della GVHD – 2018-2019

Coordinatore del progetto internazionale POINT-C, Raccomandazioni basate sull'evidenza e sul consenso all'uso di INTERFERONE per il trattamento della POLICITEMIA VERA. LeukemiaNet 2021.

Membro del gruppo di lavoro internazionale *ERS/EBMT/CIBMTR clinical practice guidelines on treatment of pulmonary chronic graft versus host disease (endorment and sponsored by the European Respiratory Society). 2021-*

#### LOCAL

- QOLONE Rev2MDS Efficacy of eltrombopag plus lenalidomide combination therapy in patients with PSS

## PRINCIPAL INVESTIGATOR

low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study

- GIMEMA "A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL)." Study LLC1114
- Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study. FONESA Foundation
- QOLONE Ecol\_MDS Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.
- GIMEMA QOL-MDS01 - Studio osservazionale per la valutazione prospettiva e prognostica della qualità di vita e dei sintomi in pazienti con sindrome mielodisplastica. Registro Internazionale PROMYS (Prognostic significance and longitudinal assessment of Patient-Related Outcomes in Myelodysplastic Syndromes (PROMYS): PROMYS International Registry)
- GIMEMA CML0912 Front-line nilotinib treatment of BCR-ABL +Chronic Myeloid Leukemia
- REPLY Study: Health resources use in patients with Chronic Lymphocytic Leukemia. Real-world evidence from Italian administrative database. CLICON
- FROM 02-2017 "Secondary cancer in myeloproliferative neoplasms (MPN-K)" A case-control international study.
- GIMEMA LLC1315 Studio osservazionale per valutare efficacia e sicurezza dell'associazione di bendamustina e rituximab in pazienti affetti da leucemia linfatica cronica
- GIMEMA ITP0714 Tasso di risposta e durata della risposta dopo l'interruzione del trattamento con gli agonisti del recettore della trombopoietina (TPO-RA) nei pazienti affetti da trombocitopenia immune primitiva (pITP): studio retrospettivo
- UNIBO: "A non-interventional observational retrospective study of Daratumumab single-agent treatment in patients with Multiple Myeloma who have received at least 3 prior lines of therapy (including a Proteasome Inhibitor and an Immunomodulatory Agent) or are double refractory to a Proteasome Inhibitor and an Immunomodulatory Agent "
- PETRA study "Studio del ruolo della FDG-PET in pazienti con linfoma follicolare al momento della recidiva/progressione" FEDERAZIONE ITALIANA LINFOMI
- GIMEMA MPN018 Patient-Reported Outcomes in Philadelphia-negative Cytogenetic myeloproliferative neoplasms (PROPHECY). A GIMEMA observational registry for Italian MPN patients

- FIL BIO\_WD "Studio osservazionale sulla diagnostica e il monitoraggio della malattia minima residua e dell'evoluzione clonale con metodiche non invasive in pazienti con diagnosi di Macroglobulinemia di Waldenström e gammopatia monoclonale di incerto significato IgM". FEDERAZIONE ITALIANA LINFOMI
- FIL-ROUGE " A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL)" FEDERAZIONE ITALIANA LINFOMI
- GIMEMA CML1415 Remissione sostenuta senza trattamento nella leucemia mieloide cronica BCR-ABL+: uno studio prospettico che confronta Nilotinib versus Imatinib con passaggio a Nilotinib in assenza di risposta ottimale
- GIMEMA "Efficacia e sicurezza in pazienti con Leucemia Linfatica Cronica (LLC) trattati con Idelalisib e Rituximab nella pratica clinica: uno studio GIMEMA-ERIC" Protocollo LLC1718
- GIMEMA Studio "Attività e sicurezza dell'associazione Venetoclax e Rituximab (VeRiTAs) in prima linea in pazienti giovani e fit con Leucemia Linfatica Cronica (LLC) non IGVH mutati e/o TP53 mutati. Studio multicentrico di fase 2" Protocollo LLC1518
- Studio fase 2b "A multi-center, open label study to assess the safety, steady-state pharmacokinetics and pharmacodynamics of IMG-7289 in patients with myelofibrosis"
- HM-COVID19-Italy: "SARS-CoV-2 infection in patients with hematological malignancies: the Italian Hematology Alliance."
- IMG-7289-CTP-201 "Studio multicentrico di fase 2 in aperto, per valutare la sicurezza, l'efficacia e la farmacodinamica di IMG-7289 in pazienti affetti da trombocitemia essenziale"
- IMG-7289-102 "Studio multicentrico di fase 2 in aperto, per valutare la sicurezza, l'efficacia e la farmacodinamica di IMG-7289 in pazienti affetti da mielofibrosi"

**ABILITAZIONE SCIENTIFICA  
NAZIONALE**

**Appartenenza a Reti/Gruppi**

Settore 06/D3 (dal 9-7-2020 al 9-7-2029)

Società Italiana di Ematologia, GIMEMA, Federazione Italiana Linfomi, LeukemiaNet, CLL-Campus

**Collaborazioni Accademiche**

Università degli Studi di Pavia – Facoltà di Ingegneria Biomedica: implementazione di linee-guida e all’elaborazione di modelli decisionali per problemi clinici

**Certificazioni**

Università CERGAS Bocconi, Milano: elaborazione di modelli decisionali volti alla definizione del profilo di costo-efficacia di nuovi device e farmaci

Iscritto all’Ordine dei Medici di Pavia dal 10 luglio 1996 (posizione n° 6907)

BLS-D: retraining 5.11.2019

ACLS: training 2008

**Formazione**

Crediti ECM dal 2008: 579

**Riconoscimenti e Premi**

Premio di Studio Biennale Gaetano Fichera per la Ricerca Oncologica conferito il 13.12.2004

Vincitore del GILEAD COMMUNITY AWARD 2016 per il progetto “P-to-p (Pazienti per i Pazienti): supporto tra pari nella gestione della Leucemia Linfatica Cronica e del Linfoma Follicolare.

**RUOLI ISTITUZIONALI**

COMITATO METODOLOGICO della COMMISSIONE LINEE-GUIDA della SOCIETA’ ITALIANA DI EMATOLOGIA dal 2001 ad oggi con il ruolo di COORDINATORE dello SVILUPPO di LINEE-GUIDA BASATE sull’EVIDENZA.

Membro della Commissione per il Technology Assessment nuovi farmaci – Regione Piemonte - settore Mieloma Multiplo (attualmente non attiva)

**DOCENZE**

UNIVERSITA’ DEL PIEMONTE ORIENTALE – CORSO DI LAUREA IN MEDICINA e CHIRURGIA – SCUOLA di SPECIALIZZAZIONE in EMATOLOGICA - DOCENTE A CONTRATTO aa 2021/2022

UNIVERSITA’ DEL PIEMONTE ORIENTALE – CORSO DI LAUREA IN IGIENE DENTALE – DOCENTE CORSO INTEGRATO DI “PRINCIPI DI MEDICINA GENERALE” (MC103 – MS0289) -- aa 2020/2021 → 2021/2022

DOCENTE -- CORSO PRATICO RESIDENZIALE -- ANALISI DECISIONALE – AGENZIA SANITARIA REGIONALE EMILIA ROMAGNA dal 01-07-2005 al 01-07-2005

DOCENTE DI ANALISI DECISIONALE -- CORSO DI II LIVELLO / MASTER -- FACOLTA’ DI ECONOMIA -- UNIVERSITA’ DI CATANIA

dal 01-04-2006 al 20-04-2006

DOCENTE UNICO CORSO FORMAZIONE GP: "Approccio pratico gestionale alle Patologie Ematologiche più frequenti per il Medico di Medicina Generale": 8 edizioni (SNAMID, Asti) dal 25-10-2014 al 30-06-2016

ORGANIZZATORE e DOCENTE del I CORSO NAZIONALE DI EMATOLOGIA BASATA SULL'EVIDENZA - TROMBOEMBOLISMO VENOSO e LEUCEMIA MIELOIDE ACUTA (Palermo) dal 10-05-2009 al 12-05-2009

ORGANIZZATORE e DOCENTE del II CORSO NAZIONALE DI EMATOLOGIA BASATA SULL'EVIDENZA - LINFOMI NON HODGKIN E LEUCEMIA LINFATICA CRONICA (Bolzano) dal 10-05-2010 al 12-05-2010

ORGANIZZATORE e DOCENTE del III CORSO NAZIONALE DI EMATOLOGIA BASATA SULL'EVIDENZA - SINDROMI MIELODISPLASTICHE E MIELOMA MULTIPLO (ASTI) dal 11-05-2011 al 13-05-2011

ORGANIZZATORE SCIENTIFICO e DOCENTE del Convegno "Sindrome da Lisi Tumorale: patogenesi, prevenzione, trattamento" (Asti) 7.10.11

ORGANIZZATORE SCIENTIFICO e DOCENTE de "Il Labirinto delle anemie: come percorrerlo?" (Asti) 27.9.12

ORGANIZZATORE SCIENTIFICO de "Come entrano le valutazioni economiche nell'attività ospedaliera?" (Asti) 27.11.12

COMUNICAZIONE ORALE al 56esimo ANNUAL MEETING dell'AMERICAN SOCIETY OF HEMATOLOGY: "Should I transplant this patient with paroxysmal nocturnal hemoglobinuria? A cost-effectiveness analysis of eculizumab versus allogeneic stem cell transplant." dal 06-12-2014 al 09-12-2014

Impatto dei nuovi farmaci sulla spesa sanitaria regionale/nazionale. RELAZIONE ORALE al meeting Nuovi approcci terapeutici nelle malattie linfoproliferative croniche (8-7-2016, Roma) il 08-07-2016

Il costo-efficacia del trattamento con idelalisib  
COMUNICAZIONE ORALE al XIV Congresso Nazionale S.I.E.S. (Società Italiana di Ematologia Sperimentale) il 20-10-2016

Raccomandazioni per la pratica clinica: validazione e implementazione. RELAZIONE ORALE al 46esimo CONGRESSO NAZIONALE della Società Italiana di Ematologia dal 15-10-2017 al 18-10-2017

Focus sulla sindrome da lisi tumorale: anche con i nuovi farmaci? RELAZIONE ORALE al convegno "Il paziente ematologico complicato" - brescia , 1 dicembre 2017

Dall'anatomia patologica alla "Real Life": applicabilità delle linee guida RELAZIONE ORALE al Corso Mieloproliferative Philadelphia Negative. Focus su Anatomia Patologica: nuovi percorsi diagnostici per le MPNs. Torino, 27.9.2019

**Presentazioni orali**

■ ASH 2021 SCIENTIFIC WORKSHOP ON



	<p>EPIDEMIOLOGY: RISK ASSESSMENT AND PREDICTION - DISCOVERY, IMPLEMENTATION AND DISPARITIES. Presentation “VTE risk prediction score in clinical practice guidelines of blood cancers: advantages and pitfalls.” 10<sup>th</sup> December 2021</p> <ul style="list-style-type: none"> <li>■ ASH 2014. Oral communication “<i>Should I transplant this patient with paroxysmal nocturnal hemoglobinuria? A cost-effectiveness analysis of eculizumab versus allogeneic stem cell transplant.</i>”</li> <li>■ ELN 7<sup>th</sup> September 2021, Mannheim. “<i>Should we treat PV irrespectively of the thrombotic risk (ELN recommendations)?</i>”</li> <li>■ ELN 9<sup>th</sup> March 2021, Virtual. “<i>POINT-C project: developing GRADE based statements and good clinical practice Consensus recommendations for Interferon use in POLycythemia vera patients</i>”</li> </ul>
<p style="text-align: center;"><b>Referee</b></p>	<p>American Journal of Hematology, Annals of Hematology, Haematologica, Journal of Medical Economics, Medical Oncology, Pharmacoeconomics, Blood Advances, Annals of Hematology, Circulation, Expert Reviews on Pharmacoeconomics and Outcomes Research</p>

## **PUBBLICAZIONI SCIENTIFICHE**

1. Marchetti M, Albertin L, Limberti G, Canicatti M. *Pharmacoeconomic consideration for acute myeloid leukemia pharmacotherapy*. **Expert Opinion on Pharmacotherapy** 2021 (in press)
2. Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, Mlimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Vbisek B, Ilhani O, Nadali G, Weinbergerova B, Cordoba-Mascunano, Marchetti M, et al. *COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)*. **J Hematol Oncol** 2021;14:168
3. Marchetti M. *Clinical practice guidelines in hematology*. **Haematologica** 2021
4. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, ALLsup D, Alonso Cabrebro A, Andreas M, Antic D, Baile M, Glenthøj B, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Juan-Ginzalo R, Correa J-G, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimous M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Anrico A, Espinet B, Farina L, Ferrari A, Frederiksen H, Foglietta M, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JA, Herold T, Innocenti I, Itchaki G, Jaksic G, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater A, Kersting S, Gomez JL, Lad D, Laurenti L, Levin M-D, Lista E, Garcia A- L, Malerba L, Marasca R, Marchetti M, et al. *COVID-19 severity and mortality in patients with Chronic Lymphocytic Leukemia: an update of the international ERIC study*. **Leukemia** 2021 (in press)
5. Rigolin GM, Del Giudice I, Bardi MA, Mlenadri A, Edith R, Jacob G, Cafforio L, Piciocchi A, Arena V, Reda G, Albano F, Molica S, Sportoletti P, trentin L, Marchetti M, Nanni M, Peragine N, Mariglia P, Vignetti M, Guarini A, Mauro F, Foà R, Cuneo A. *Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab. The GIMEMA LLC1114 phase 2 study*. **Blood** 2021 in press. BLD-2021-011883R2
6. Marchetti M, et al. *Primary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies (lymphoma, myeloma, acute leukemia)*. *Guidelines from the Italian Society of Hematology*. **Haematologica** 2021.
7. Visco C, Marcheselli L, Mina R, Ferreri AJM, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Gaidano G, Martelli M, Cairoli R, Salvini M, Bertù L, Ladetto M, Vannucchi AM, Pinto A, Tarella C, Marchesi F, Cavo M, Arcaini L, Angelucci E, Di Raimondo F, Musto P, Massaia M, Fracchiolla N, Marchetti M, Scattolin A, Ruggeri M, Cuneo A, Della Porta M, Trentin L, Turrini M, Gherlinzoni F, Tafuri A, Galimberti S, Bocchia M, Falini B, Cilloni D, Corso A, Avvisati G, Rigacci L, Ortu La Barbera E, Gambacorti Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Corradini P, Passamonti F, and Merli F on behalf of the ITA-HEMA-COV Investigators. *A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study*. **Blood Advances** 2021 (in press)
8. Passamonti F, Romano A, Salvini M, Merli F, Della Porta MG, Bruna R, Angelucci E, Romano I, Cairoli R, Lemoli R, Farina F, Venditti A, Busca A, Ladetto M, Massaia M, Pinto A, Arcaini L, Tafuri A, Marchesi

- F, Fracchiolla N, Bocchia M, Armiento D, Candoni A, Krampera M, Luppi M, Falini B, Galimberti S, Cattaneo C, Ortu La Barbera E, Mina R, Lanza F, Visani G, Musto P, Martelli M, Lanza F, Visani G, Musto P, Martelli M, Zaja F, Dernezini E, Marchetti M, et al. on behalf of the ITA-HEMA-COV Investigators (Derenzini E, Marchetti M, Scattolin AM, Corso A, Tosi P, Gherlinzoni F, Passerini CG, Cavo M, Fava C, Turrini M, Visco C, Grossi PA, Zappasodi P, Merli M, Mora B, Vannucchi AM). *Covid-19 elicits an impaired antibody response against SARS-CoV-2 in patients with hematological malignancies*. **British Journal of Haematology** 2021 (in press)
9. Marchetti M, Gale RP, Barosi G. *Cost-effectiveness of post-autotransplant lenalidomide in persons with plasma cell myeloma*. **Mediterranean J Hematol and Infect Dis**. 2021 (in press)
  10. Rigolin GM, et al Marchetti M. et al. *Efficacy of idelalisib and Rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials*. A report of the GIMEMA Working Group. **Hematol Oncol** 2021. Doi: 10.1002/hon.2861
  11. Baronciani D, Casale M, De Franceschi L, Graziadei G, Longo F, Origa R, Rigano P, Pinto V, Marchetti M, Gigante A, Forni G. *Selecting  $\beta$ -thalassemia Patients for Gene Therapy: A Decision-making Algorithm*. **HemaSphere**-2020-0278R1
  12. Vitale C, Salvetti S, Griggio V, Porrazzo M, Schiattone L, Zamprogna G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccillato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, tedeschi A, Scarfò Lydia, Gaidano G, Mauro F, Foà R, Boccadoro M, Marta Coscia. *Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs*. **Blood** 2021 (in press) BLD-2020-008201R1
  13. Marchetti M. *Clinical practice guidelines in hematology*. **Haematologica** 2020;105 (suppl 2): S7-S8
  14. Cuneo A, Mato A, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan J, Pagel J, Brander D, Hill B, Allison W, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr P, Shadman M, Skarbnik A, Pu J, Sehgal A, Schuster S, Shah N, Ujjani C, Roeker L, Orlandi E, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, et al. *Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and U.S. study*. **Cancer Medicine** 2020;9(22):8468-8479 DOI: 10.1002/cam4.3470
  15. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli M, Molteni A, Busca A, Cuneo A, et al. *Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with hematological malignancies in Italy: a multicentre, cohort study*. **The Lancet Haematology** 2020;7(10):e737-e745
  16. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernandez J, Mirás F, Baile M, Marquet J, Niemann C, Reda G, Munir T, Gimeno E, Monia Marchetti, Quaglia FM, et al. *COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus*. (reference number: 20-LEU-0964). **Leukemia** 2020;34(9):2354-2363.

17. Marchetti M, Zinzani PL, Feyles E. Frontline Siltuximab and Rituximab in TAFRO syndrome: a case report. **Eur J Haematol** 2020;105:505-507. doi: [10.1111/ejh.13473](https://doi.org/10.1111/ejh.13473)
18. Marchetti M. COVID-19-driven endothelial damage: complement, HIF-1 and ABL2 are potential pathways of damage and targets for cure. **Ann Hematol** 2020;99(8):1701-1707.
19. Cuneo A, Scarfo L, Reda G, Varettoni M, Quaglia F, Marchetti M, De Paoli L, Re F, Pietrasanta D, Rigolin GM, Orsucci L, Ibatucci A, Gattei V, Mauro F, Trentin L, Laurenti L, Marasca R, Foa R. *Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a campus CLL report.* **Blood** 2020 (in press) doi: [10.1182/blood.2020006854](https://doi.org/10.1182/blood.2020006854)
20. Visentin A, Nasillo V, Marchetti M, Ferrarini I, Paolini R, Sancetta R, Rigolin GM, Cibien F, Riva M, Briani C, Marinello S, Piazza F, Gherlinzoni F, Krampera M, Bassan M, Cuneo A, Luppi M, Semenzato G, Marasca R, Trentin L. *Clinical characteristics and outcome of West Nile Virus infection in patients with lymphoid neoplasms: an Italian multicenter study.* **HemaSphere** 2020 (in press)
21. Mina R, Belotti A, Petrucci MT, Zambello R, Capra A, Di Lullo G, Ronconi S, Pescosta N, Grasso M, Monaco F, Cellini C, Gobbi M, Ballanti S, De Fabritiis P, Mosca-Siez ML, Marchetti M, Liberati AM, Offidani M, Giuliani N, Ria R, Musto P, Romani A, Sonneveld P, Boccadoro M, Larocca A. *Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.* **Blood Cancer Journal** 2020;10(5):58 (20-BCJ-0175RR) *Blood Cancer J.* 2020 May 18;10(5):58. doi: [10.1038/s41408-020-0326-1](https://doi.org/10.1038/s41408-020-0326-1).
22. Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Ecinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. *Second cancers in MPN: a survival analysis from an international study.* **Am J Hematol** 2020;95(3):295-301. doi: [10.1002/ajh.25700](https://doi.org/10.1002/ajh.25700). Epub 2019 Dec 22.
23. Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V, on behalf of MPN-K authors. *Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin.* **Leukemia** 2020;34(8):1208-1209. doi: [10.1038/s41375-019-0616-4](https://doi.org/10.1038/s41375-019-0616-4). Epub 2019 Nov 7.
24. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Ecinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. *Arterial thrombosis in myeloproliferative neoplasms predicts second cancer. Clinical observations in a case-control study.* **Blood** 2020;135(5):381-386. doi: [10.1182/blood.2019002614](https://doi.org/10.1182/blood.2019002614).
25. Penack O, Marchetti M, Tapani R, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Shoemans H, Socié G, Solano C, Vrhovac R, Zeiser, Kroger N, Basal GW. *Prophylaxis*

- and management of graft versus host disease after stem cell transplantation for malignant haematologic malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. **Lancet Hematology** 2020;7(2):e157-e167. doi: [10.1016/S2352-3026\(19\)30256-X](https://doi.org/10.1016/S2352-3026(19)30256-X).
26. Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magiulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M. *HIF-1alpha is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia*. **Haematologica** 2020;105(4):1042-1054. doi: [10.3324/haematol.2019.217430](https://doi.org/10.3324/haematol.2019.217430). Epub 2019 Jul 9.
  27. Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, Tura S, Barosi G. *Infection control in patients candidate to treatment with ibrutinib or idelalisib in chronic lymphocytic leukemia: recommendations from Italian Society of Hematology*. **Leuk Res** 2019;81:88-94.
  28. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, de Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonificaio M, Scaffidi L, Patriarca A, Rumi E, Stephenson C, Guglielmelli P, Elli EM, Miroslava P, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox , Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi F, Racasens Flores V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi A, Finazzi G. *Second cancer in Philadelphia negative Myeloproliferative neoplasms (MPN-K). A nested case-control study*. **Leukemia** 2019;33:1996-2005
  29. Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda L, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. *Short course of bortezomib in anemic patients with relapsed cold agglutinin disease. A phase II prospective GIMEMA study*. **Blood** 2018 Aug 2;132(5):547-550.
  30. Crisa E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D. *The use of erythropoiesis-stimulating agents is safe and effective in the management of anemia in myelofibrosis patients treated with ruxolitinib*. **Br J Haematol**. 2018 Sep;182(5):701-704.
  31. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum. *Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study* **Haematologica** 2018 Jul;103(7):1209-1217.
  32. Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R, Verstovsek S, Mesa R, Kiladjan JJ, Helhmann R, Reiter A, Cervantes F, Harrison C, McMullin MF, Hasselbach H, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. *Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management*

- recommendations from European LeukemiaNet. Leukemia* 2018; 32(5):1057-1069. doi: 10.1038/s41375-018-0077-1.
33. Marchetti M, Carobbio A, Capitoni E, Barbui T. *Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review. Am J Hematol* 2018;93:698-703 doi: 10.1002/ajh.25049.
  34. Marchetti M, Montillo M, Cuneo A, Mauro FR, Martelli E, Pedone MP. *Cost-effectiveness of idelalisib-rituximab for the treatment of relapsed-refractory chronic lymphocytic leukemia. Hematology International Journal* 2017;1(1):000106 (ISSN: 2578-501X indexed RsearchBib. doi: [10.23880/hij-16000106](https://doi.org/10.23880/hij-16000106)
  35. Marchetti M. *Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res* 2017;17:469-80
  36. Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T. *Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia* 2017;31:882-8.
  37. Piubelli C, Castagna A, Marchi G, Rizzi M, Busti F, Badar S, Marchetti M, De Gobbi M, Roetto A, Xumerle L, Suku E, Giorgetti A, Delledonne M, Olivieri O, Girelli D. *Identification of new BMP6 pro-peptide mutations in patients with iron overload. Am J Hematol* 2017;92:562-8
  38. Marchetti M. *Value of innovation for hematologic malignancies. J Med Econ* 2016;19:487-9.
  39. Liberato NL, Marchetti M. *Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Rev Pharmacoecon Outcomes Res* 2016;16:221-35.
  40. Marchetti M, Liberato NL. *Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res.* 2014 Dec;14(6):815-24.
  41. Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S. *Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk.* 2015 Feb;15(2):75-85
  42. Cuneo A, Marchetti M, Barosi G, Billio A, et al. *Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk Res* 2014;38:1269-77
  43. Rognoni C, Marchetti M, Quaglini S, Liberato NL. *Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis.* 2015 Feb;39(2):149-54.
  44. Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, Pimpinelli N, Rossi G, Zinzani PL, Tura S. *SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukemias. Ann Oncol* 2014;25(12):2339-50

45. Perseghin P, Marchetti M, Pierelli L, Olivieri A, Introna M, Lombardini L, Accorsi P, Petrini C, Risso M, Bosi A. *A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel*. **Transfusion** 2014;54:2353-60
46. Olivieri J, Pierelli L, Introna M, Accorsi P, Bosi A, Perseghin P, Risso M, Pandolfi A, Mancini S, Marchetti M, Dal Pozzo S, Gotti E, Rambaldi A, Leoni P, Olivieri A, GITMO-SIDEM Working group on SCU Disposal. *Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey*. **Cytotherapy** 2014;16:101-10.
47. Bassetti M, Marchetti M, Chakrabati A, Colizza S, Garnacho-Montero J, Lett D, Munoz P, Cristini F, Andoniadou A, Viale P, Della Rocca G, Roilides E, Sganga G, Walsh TJ, Tascini C, Tumbarello M, Menichetti F, Righi E, Eckmann C, Viscoli C, Shorr AF, Leroy O, Petrikos G, De Rosa FG. *A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts*. **Intensive Care Med** 2013;39:2092-106
48. Rognoni C, Marchetti M, Quaglini S, Liberato NL. *Apixaban, Dabigatran, and Rivaroxaban versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: a Cost-Effectiveness Analysis*. **Clinical Drug Investigation** 2014;34(1):9-17.
49. Perseghin P, Marchetti M, Messina C, Mazzoni A, Carlier P, Perotti C, Salvaneschi L, Risso M, Fanin R, Olivieri A, Accorsi P, Locatelli F, Bacigalupo A, Pierelli L, Bosi A. *Best practice recommendations in (1) peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SidEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo)*. **Transfus Apher Sci** 2013;48(2):195-6.
50. Zinzani PL, Marchetti M, Billio A, Barosi G, Carella AM, Lazzarino M, Martelli M, Rambaldi A, Rigacci L, Tarella C, Vitolo U, Tura S; Expert Panel of the Italian Society of Hematology. *SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma*. **Am J Hematol** 2013 Mar;88(3):185-92. [IF 6.862]
51. Catania G, Bell C, Ottonelli S, Marchetti M, Bryce J, Grossi A, Costantini M. *Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI)*. **Support Care Cancer** 2013 Feb;21(2):413-9.
52. Pierelli L, Perseghin P, Marchetti M, Messina C, Perotti C, Mazzoni A, Bacigalupo A, Locatelli F, Carlier P, Bosi A. *Extracorporeal photopheresis for the treatment of acute and chronic GvHD in adults and children – best practice recommendations from a SIDEM (Società Italiana di Emaferesi e Manipolazione cellulare) and GITMO (Gruppo Italiano Trapianto Midollo Osseo) consensus process*. **Transfusion** 2013 ;53:2340-52. [IF 2012 = 3.2]
53. Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. *Cost-effectiveness of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease*. **Eur J Health Econ** 2013 Dec;14(6):853-61 [IF 2011 = 1.5]
54. Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S. *SIE, SIES, GITMO evidence-based guidelines on novel agent (thalidomide, bortezomib and lenalidomide) in the treatment of multiple myeloma*. **Ann Hematol** 2012;91:875-88. [IF year 2012 = 2.61]



55. Liberato NL, Rognoni C, Rubrichi S, Quaglini S, Marchetti M, Gorlia T, Licitra L, Vermorken JB. *Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.* **Annals of Oncology** 2012;23:1825-32. [IF year 2012 = 6.42]
56. Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. *Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.* **Intern Emerg Med.** 2011 Oct;6 Suppl 1:17-27. [IF 2012 = 2.05]
57. Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U. *Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.* **Leuk Lymphoma.** 2011;53:789-95. [IF year 2011 = 2.58]
58. Mauro FR, Bandini G, Barosi G, Billio A, Brugiattelli M, Cuneo A, Lauria F, Liso V, Marchetti M, Meloni G, Montillo M, Zinzani P, Tura S. *SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.* **Leuk Res.** 2011; 36(4):459-66.[IF year 2011 = 2.92]
59. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, Rambaldi A, Bosi A. *Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo.* **Bone Marrow Transplantation** 2011 47(3):342-51. [IF year 2011 = 3.74]
60. Pierelli L, Perseghin P, Marchetti M, Accorsi P, Fanin R, Messina C, Olivieri A, Risso M, Salvaneschi L, Bosi A for SIDEM and GITMO. *Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a SIDEM and GITMO consensus process.* **Transfusion** 2011;52:893-905. [IF year 2011 = 3.2]
61. Casabianca A, Marchetti M, Zallio F, Feyles E, Concialdi E, Ferroglio E, Biglino A. *Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment.* **Infection** 2011 Aug;39(4):375-8. [IF year 2011 = 2.66]
62. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S. *Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.* **Leuk Res** 2010;34(12):1576-88. [IF year 2010 = 2.55]
63. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, Marchetti M, Santoro A, Zinzani PL, Tura S. *Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.* **Haematologica** 2009 Apr;94(4):550-65 [IF year 2009: 6.41]
64. Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, Martinelli G, Mecucci C, Vignetti M, Tura S. *Clinical management of primary non-APL Acute Myeloid Leukemia: practice guidelines by the Italian Society of Haematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.* **Haematologica** 2009 Jan;94(1):102-12. [IF year 2009: 6.41]
65. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, Pession A, Rosti G, Santoro A, Zinzani PL, Tura S. *Consensus conference on the management of tumor lysis syndrome.* **Haematologica** 2008;93:1877-85. [IF year 2007: 5.516]
66. Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian



- Group for Bone Marrow Transplantation. *Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica*. 2008;93:1364-71. [IF year 2008: 5.98]
67. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S. *Italian Society Haematology Practice Guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica* 2008; 93: 741-52. [IF year 2008: 5.98]
68. Maserati E, Pressato B, Valli R, Patitucci F, Lo Curto F, Pasquali F, Minelli A, Danesino C, Marchetti M, Barosi G. *Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. Cancer Genetics and Cytogenetics* 2007; 179: 79-81. [IF year 2007 = 1.55]
69. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T. *JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood* 2007;110:4030-6 [IF year 2007: 10.89]
70. Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G. *The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Molecules and Diseases* 2007;38:280-6 [IF year 2007: 2.55]
71. Liberato NL, Marchetti M, Barosi G. *Cost-effectiveness of adjuvant trastuzumab in human epidermal growth factor 2 – positive breast cancer. Journal of Clinical Oncology* 2007;25:625-33 [IF year 2007: 15.48]
72. Marchetti M, Kuhnel UM, Colombo G, Esposito S, Principi N. *Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Human Vaccines* 2007;3:14-22
73. Brugiattelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, Mauro FR, Meloni G, Zinzani PL, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. *Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica* 2006 Dec;91(12):1662-73. [IF year 2006: 5.032]
74. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, Vitolo U, Zinzani PL, Tura S. *Management of nodal diffuse-large-B-cell lymphomas: practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica* 2006 Jan;91(1):96-103. [IF year 2006: 5.032]
75. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, Vitolo U, Zinzani PL, Tura S. *Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphoma: practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica* 2005;90:1237-1257. [IF year 2005: 4.575]

76. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory J-L, Dupriez B, Gisslinger H, Griesshammer M, Hasselbach H, Le Bousse-Kerdiles M-C, Liberato NL, Marchetti M, Reilly JT, Thiele J. *Response criteria for Myelofibrosis with Myeloid Metaplasia: Results of an Initiative of the European Myelofibrosis Network (EUMNET)*. **Blood** 2005;106:2849-53 [IF year 2005: 10.131]
77. Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Hoffman R, Barosi G, on behalf of the Investigators of the Italian Registry of Myelofibrosis with Myeloid Metaplasia. *Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia*. **Journal of Clinical Oncology** 2005;23:5688-5695. [IF year 2005: 11.310]
78. Marchetti M, Colombo G. *Cost-effectiveness of universal pneumococcal vaccination for infants in Italy*. **Vaccine** 2005; 23:4565-76. [IF 2005: 3.00]
79. Huges DA, Marchetti M, Colombo G. *Cost minimization of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive gastroesophageal reflux disease – a Monte Carlo analysis for Italy*. **Expert Reviews in Pharmacoeconomics and Outcomes Research** 2005;5:29-38.
80. Marchetti M, Barosi G, Balestri F, et al. *Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial of 63 patients*. **Journal of Clinical Oncology** 2004;22: 424-31. [IF year 2004: 9.8]
81. Marchetti M, Cavallo MC, Annoni E, Gerzeli S. *Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma*. **Expert Review in Pharmacoeconomics and Outcomes Research** 2004;4:549-564.
82. Marchetti M. *Drug-eluting stents: from evidence to policy*. **Expert Review in Medical Device** 2004;1:49-63
83. Barosi G, Rosti V, Massa M, Viarengo GL, Pecci A, Necchi V, Ramaioli I, Campanelli R, Marchetti M, Bazzan M, Magrini U. *Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia*. **Br J Haematol** 2004;124:618-625. [IF year 2004: 3.19]
84. Barbui T, Barosi G, Grossi A, Gugliotta A, Liberato NL, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. *Evidence- and Consensus-Based Practice Guidelines for the Therapy of Essential Thrombocythemia. A statement from SIE, SIES and GITMO (Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation)*. **Haematologica** 2004;89:215-32. [IF year 2004: 4.19]
85. Tarricone R, Marchetti M, Lamotte M, Annemans L, de Jong P. *What reimbursement for coronary revascularization with drug-eluting stents?* **Eur J Health Econ** 2004;5:309-16.
86. Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini GP, Tosi P, Tura S. *Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)*. **Haematologica** 2004;89:717-741 [IF year 2004: 4.19]
87. Marchetti M, Barosi G. *Clinical and economic impact of epoetins in cancer care: a review*. **Pharmacoeconomics** 2004;22:1029-45 [IF year 2004: 1.95]

88. Marchetti M, Caruggi M, Colombo G. *Cost-utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer*. **Clin Ther** 2004; 26:1546-1561. [IF year 2004: 3.01]
89. Liberato NL, Marchetti M, Barosi G. *Clinical and economic issues in bisphosphonates treatment of advanced breast cancer*. **Drugs and Aging** 2003; 20: 631-642 [IF year 2003: 2.799]
90. Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M. *Chronic myeloproliferative disorders*. **Hematology** 2003:199-223.
91. Marchetti M, Barosi G. *Screening for factor V Leiden mutation in pregnant women*. **Lancet** 2002;360:1518. [IF year 2002: 15.39]
92. Barosi G, Salvaneschi L, Grasso M, Martinetti M, Marchetti M, Bodini U, Reggiani A, D'Agostino F, Nalli G, Degiuli A, De Silvestri A, Arbustini E. *High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy*. **Haematologica** 2002;87:472-478. [IF year 2002: 3.22]
93. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato NL, Locatelli F, Marchetti M, Morra E, Rebulli P, Visani G, Tura S. *Evidence- and consensus-based guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology*. **Haematologica** 2002;87:1286-1306. [IF year 2002: 3.22]
94. Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A. *Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from 5 studies*. **Leuk Lymph** 2002; 43 : 2301–2307. [IF year 2002: 1.33]
95. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, Frassoni F, on behalf of the Investigators of the Italian Registry of Myelofibrosis with Myeloid Metaplasia. *Diagnostic and clinical relevance of the number of circulating CD34-positive cells in myelofibrosis with myeloid metaplasia*. **Blood** 2001;98:3249-55. [IF 9.27]
96. Marchetti M, Quaglini S, Barosi G. *Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A*. **Quarterly Journal of Medicine** 2001; 94:365-372. [IF 2.6]
97. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. *Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: cost-effectiveness analysis*. **Am J Med** 2001; 111:130-139. [IF 6.1]
98. Marchetti M, Liberato NL, Barosi G. *Pharmacoeconomics of fludarabine as first-line therapy for CLL*. **N Engl J Med** 2001;344:1166-7. [IF 29.06]
99. Barosi G, Grossi G, Comotti B, Musto P, Gamba G, Marchetti M. *Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia*. **Br J Haematol** 2001;114:78-83. [IF 2.81]
100. Cervantes F, Barosi G, Hernandez-Boluda JC, Marchetti M, Monserrat E. *Myelofibrosis with myeloid metaplasia in individuals 30 years old or younger individuals: presenting features, evolution and survival*. **Eur J Haematology** 2001; 66:423-427. [IF 1.67]
101. Gerli GC, Gianelli U, Carrara MC, Bestetti A, Marchetti M, Barosi G. *Myelofibrosis with myeloid metaplasia with fatty bone marrow: report of a new case*. **Haematologica** 2001 Aug;86:885-6 [IF 3.21]
102. Marchetti M, Barosi G. *Cost-effectiveness of epoetin for reducing allogeneic blood transfusions in coronary artery by-pass*. **Transfusion** 2000;40:673-81. [IF 3.04]

103. Magni P, Quaglini S, Marchetti M, Barosi G. *Deciding when to intervene: the Markov decision planning approach for managing uncertainty about intervention-time*. **International Journal of Medical Informatics** 2000;60:237-53. [IF 0.69]
104. Marchetti M, Pistorio A, Barosi G. *Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis*. **Thrombosis and Haemostasis** 2000;84:752-7. [IF 4.37]
105. Barosi G, Marchetti M, on behalf of the RIMM Investigators. *The Italian Registry of Myelofibrosis is one year old*. **Haematologica** 2000;85:1121-2. [IF 2.53]
106. Barosi G, Marchetti M. *The clinical utility of epoetin in cancer patients: a matter of perspective*. **Haematologica** 2000;85:449-50. [IF 2.53]
107. Marchetti M, Liberato NL, Ruperto N, Barosi B. *Long term cost-effectiveness of low-molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement*. **Haematologica** 1999;84(8):730-7. [IF 2.07]
108. Barosi G, Marchetti M, Alessandrino P, Locatelli F, Casula S, Lunghi M, Cazzola M, Giraldi E, Bernasconi C. *A model for analyzing the costs of autologous peripheral blood progenitor cells (PBPC) transplantation*. **Bone Marrow Transplantation** 1999;23:719-25. [IF 2.27]
109. Quaglini S, Dazzi L, Stefanelli M, Barosi G, Marchetti M. *Decision support systems in health economics*. **Top Health Inf Manage** 1999;20:16-30.
110. Marchetti M, Quaglini S, Barosi G. *Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis. Analyzing the decision in different clinical scenarios*. **Journal of Internal Medicine** 1998;244:217-26. [IF 1.53]
111. Barosi G, Marchetti M, Liberato NL. *Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia*. **British Journal of Cancer** 1998;78:781-787. [IF 3.03]
112. Barosi G, Marchetti M, Dazzi L, Quaglini S. *Testing for occult cancer in patients with idiopathic deep vein thrombosis – A decision analysis*. **Thrombosis and Haemostasis** 1997;78:1319-1326. [IF 4.58]
113. Marchetti M, Liberato NL, Barosi G. *Beyond Bayes*. **Haematologica** 1996;81:253-7. [IF 1.4]
114. Barosi G, Marchetti M, Quaglini S. *Cost-effectiveness of post-routine screening for an occult cancer in patients with idiopathic venous thromboembolism*. **Haematologica** 1995;80 (Suppl. issue n.2): 61-65. [IF 1.2]

#### PUBBLICAZIONI IN LINGUA ITALIANA

1. Barosi G, Marchetti M, Liberato NL. *La terapia delle sindromi mielodisplastiche- Linee-guida su evidenza e consenso – La metodologia dell'evidenza e del consenso per le linee-guida*. **Haematologica** 2002; 87 (suppl 3):2-4. [IF year 2002: 3.22]
2. Barosi G, Marchetti M, Longo G. *La terapia del mieloma multiplo - La metodologia dell'evidenza e del consenso per le linee guida*. **Haematologica** 2003;87:2-4. [IF year 2003: 3.45]

3. Barosi G, Marchetti M, Liberato LN. *La terapia della trombocitemia essenziale - Metodologia dell'evidenza e del consenso per le linee-guida*. **Haematologica** 2003;88 (suppl 11): 2-4. [IF year 2003: 3.45]
4. Di Michele D, Marchetti M, Magrini U, Di Pietro E, Pomante R, Barosi G. *Metaplasia mieloide: un criterio necessario per la diagnosi di mielofibrosi in pazienti asplenic*. **Giornale Italiano di Medicina Interna** 2006;5:112-114.
5. Marchetti M, Colombo GL. *Considerazioni cliniche ed economiche nel trattamento del cancro alla prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH*. **Farmacoeconomia e Percorsi Terapeutici** 2003; 4 (3): 153-168.

PUBBLICAZIONE ITALIANA LIBRO DI TESTO

Barosi G, Marchetti M, Liberato NL, Ruperto N. *Metodologia della diagnosi medica: cap I (pp3-47) in: Progressi I – Fisiopatologia e Clinica – Diagnostica – Farmacoterapia*. Collana: **RECENTIA in MEDICINA**. UTET, Torino 2002.

Benevolo G, Beggiato E, Biolé CA, Marchetti M, Melchio L, Milan A, Rapezzi D, Sartori C. *Gestione del rischio cardiovascolare nella Policitemia vera*. Collana: **In Focus**. Springer Healthcare Communications 2021

Alessandria, 11 novembre 2021

